Myriad Genetics, Inc.

Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers

Myriad Genetics announced new MONSTAR-SCREEN-3 data showing its WGS-based Precise MRD platform detected residual disease with ultra-sensitivity in resectable colorectal and pancreatic cancers. In colorectal cancer, post-surgical ctDNA was detected ahead of all observed recurrences with a median four-month lead time; more than half of positives were found below 100 parts per million. In pancreatic cancer, a historically low-shedding tumor type, personalized panels were built for all evaluable patients and MRD detection at one month correlated with worse recurrence-free survival. The findings will be presented at ESMO Congress 2026 on October 25, adding commercial evidence for the Precise MRD franchise but with no immediate revenue or regulatory consequence.

•10d ago

Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp

Labcorp entered a definitive agreement to acquire Myriad Genetics' Prenatal Health testing business for $210 million in cash plus the value of inventory at closing. The acquired portfolio includes the Prequel, Foresight, SneakPeek and FirstGene tests, used by over 600,000 patients in the last twelve months. Labcorp expects the deal to add approximately $160 million of revenue in year one and be slightly accretive to adjusted earnings. The transaction is subject to regulatory clearance and is expected to close by early 2027, with Labcorp management framing it as a fit with its specialty testing growth strategy.

•12d ago

Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology

Myriad Genetics and SOPHiA GENETICS announced a collaboration to advance Myriad's PrGIS prostate cancer genomic instability score toward clinical trials and potential companion diagnostic use, with AstraZeneca also involved. PrGIS, designed to assess chromosomal instability tied to homologous recombination deficiency in prostate cancer, will be produced by Myriad's MyChoice CDx test, now being advanced for a new prostate cancer indication. SOPHiA GENETICS will build PrGIS into a decentralized companion diagnostic across its network of 1,000+ institutions in 75+ countries, and Myriad plans to present co-authored PrGIS research with AstraZeneca at ESMO Congress 2026. No financial terms were disclosed, so the near-term revenue impact is limited, but it strengthens Myriad's biopharma companion diagnostics franchise.

•24d ago

SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology

Myriad Genetics and SOPHiA GENETICS announced a collaboration to advance Myriad's prostate cancer-specific genomic instability score (PrGIS) technology with AstraZeneca, aimed at supporting HRD as an actionable biomarker in precision oncology. Myriad's MyChoice CDx test, already a companion diagnostic in ovarian cancer, will produce the PrGIS score, while SOPHiA GENETICS develops a decentralized companion diagnostic solution incorporating PrGIS for its global network of more than 1,000 institutions in over 75 countries. Myriad and AstraZeneca co-authored PrGIS research to be presented at ESMO Congress 2026, expected to further validate the biomarker. No financial terms of the collaboration were disclosed.

•24d ago

Myriad Genetics Launches FirstGene® Multiple Prenatal Screen

Myriad Genetics announced the full commercial launch of the FirstGene Multiple Prenatal Screen, the only lab test to run four prenatal genetic screens simultaneously from a single blood draw as early as eight weeks gestation. The test delivers fetal chromosome, fetal single-gene, patient carrier, and fetal RhD screening in one integrated report with greater than 98% analytical sensitivity and greater than 99% analytical specificity, with results expected in approximately 10 days. This launch expands Myriad's comprehensive prenatal screening portfolio, aiming to streamline the historically fragmented screening process and provide clinicians with actionable insights earlier in pregnancy.

•3mo ago

New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer

Myriad Genetics announced the publication of the largest meta-analysis to date for its Prolaris Biopsy Test in Clinical Genitourinary Cancer. The analysis pooled data from 14 studies involving 8,478 patients, demonstrating that the test provides independent prognostic information for metastasis and prostate cancer-specific mortality beyond standard clinical risk groups. These findings support the role of Prolaris in risk stratification and shared decision-making for the management of localized prostate cancer.

•4mo ago

Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication

Myriad Genetics has expanded the availability of its Precise MRD test to include breast, colorectal, and renal cancers, addressing a patient population of more than 6 million in the U.S. The expansion is supported by data from the prospective MONITOR-Breast study published in Future Oncology, which demonstrated 100% specificity in predicting pathological complete response and identified 44% more at-risk patients through longitudinal testing. Management highlighted that the whole-genome sequencing-based assay offers ultrasensitive ctDNA detection to help guide treatment and surveillance decisions across the cancer care continuum.

•4mo ago

Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting

Myriad Genetics is presenting six posters at the 2026 ASCO Annual Meeting, highlighting the prognostic power of its Precise MRD assay across diverse solid tumors. Interim data from the MONSTAR-SCREEN-3 study, led by Dr. Takayuki Yoshino, shows 97% baseline detection and 16% ultrasensitive detection, with ctDNA positivity strongly correlating with recurrence risk. The company emphasizes that its whole-genome sequencing approach captures clinically meaningful signals at low ctDNA levels, potentially establishing a new standard for clinical decision-making in oncology.

•5mo ago

Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)

Myriad Genetics launched Prolaris + AI, the first prostate cancer biomarker test to combine clinical-pathological features, molecular scoring, and AI-powered digital pathology. The test leverages technology from PATHOMIQ AI to help clinicians identify patients safe for active surveillance and personalize surveillance intensity, addressing a gap in traditional pathology tools. Validation studies showed the AI metric is a statistically significant predictor of Gleason upgrade at follow-up biopsy, independent of other clinical variables. The new metric is available for U.S. tests (excluding New York) starting May 29, 2026.

•5mo ago

Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life

Myriad Genetics has partnered with actress Jackie Tohn to raise awareness for its MyRisk Hereditary Cancer Test, leveraging her personal story of discovering a BRCA1 variant. Tohn, known for Netflix’s 'Nobody Wants This,' underwent testing after her father’s cancer diagnosis, learning she had an 85% lifetime risk of breast cancer and a 65% risk of ovarian cancer. The campaign highlights the MyRisk test’s ability to assess risk across 11 cancer types using 63 genes and ~150 genetic markers, aiming to drive proactive screening among under-tested demographics like Ashkenazi Jewish women.

•5mo ago

Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business

Myriad Genetics reported Q1 2026 revenue of $200.4 million, up 2% year-over-year, driven by growth in the Cancer Care Continuum and Mental Health segments which offset a decline in Prenatal Health. The company reaffirmed its full-year 2026 guidance for revenue of $860-$880 million and adjusted EBITDA of $37-$49 million. Strategic milestones included the FDA approval of MyChoice CDx as a companion diagnostic for Zejula in advanced ovarian cancer and the launch of the Precise MRD assay. Management noted positive early feedback on the limited launch of Precise MRD for breast cancer and remains on track for additional planned launches in 2026.

•5mo ago